Figure 6
From: A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer
CMT organoids can be used to perform large-scale CRISPR/Cas9 screening. (a) Outline of the screen performed with a custom CRISPR/Cas9 library. (b) Histogram representing the distribution of the gRNA counts for the plasmid DNA (pDNA). (c) Histogram representing the distribution of the gRNA counts for ORG-63-N at D0 (replicate 1). (d) Volcano plot representing depleted (Log Fold Change = LFC < 0) and enriched (LFC > 0) genes for ORG-63-N 12 days after transduction (D0 vs. pDNA). LFC and P-values were calculated from two independent replicates with MAGeCK analysis. Each dot represents one gene for which at least three gRNAs (out of 6) were significant. Top hits are labeled with gene names. (e) Volcano plot representing depleted (Log Fold Change = LFC < 0) and enriched (LFC > 0) genes for ORG-63-C 12 days after transduction (D0 vs. pDNA). LFC and P-values were calculated from two independent replicates with MAGeCK analysis. Each dot represents one gene for which at least three gRNAs (out of 6) were significant. Top hits are labeled with gene names.
